Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan A Grupp

Showing results (211-220 of 238) with videos related to

Pageof 24
Sort By:
Nature Medicine|October 3, 2018
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cellMarco Ruella, Jun Xu, David M Barrett, et al.
Cancer Discovery|October 31, 2015
Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 ImmunotherapyElena Sotillo, David M Barrett, Kathryn L Black, et al.
Blood Advances|October 23, 2020
Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill childrenCaroline Diorio, Pamela A Shaw, Edward Pequignot, et al.
Journal for Immunotherapy of Cancer|October 26, 2019
Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcomaIndu Ramachandran, Daniel E Lowther, Rebecca Dryer-Minnerly, et al.
Blood Advances|April 28, 2022
Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cellsAdam J Lamble, Regina M Myers, Agne Taraseviciute, et al.
Journal for Immunotherapy of Cancer|December 18, 2020
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse eventsMarcela V Maus, Sara Alexander, Michael R Bishop, et al.
Blood Advances|February 11, 2026
CCR4 expression defines a targetable subset of T-cell acute lymphoblastic leukemiaJason Xu, Michael McCoy, Zachary Martinez, et al.
Journal for Immunotherapy of Cancer|April 17, 2025
CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapyRegina M Myers, Amanda M DiNofia, Yimei Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2021
Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic LeukemiaRegina M Myers, Yimei Li, Allison Barz Leahy, et al.
Blood|January 31, 2016
Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failurePaul G Richardson, Marcie L Riches, Nancy A Kernan, et al.
Pageof 24

Showing results (211-220 of 238) with videos related to

Sort By:
Pageof 24
Nature Medicine|October 3, 2018
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cellMarco Ruella, Jun Xu, David M Barrett, et al.
Cancer Discovery|October 31, 2015
Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 ImmunotherapyElena Sotillo, David M Barrett, Kathryn L Black, et al.
Blood Advances|October 23, 2020
Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill childrenCaroline Diorio, Pamela A Shaw, Edward Pequignot, et al.
Journal for Immunotherapy of Cancer|October 26, 2019
Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcomaIndu Ramachandran, Daniel E Lowther, Rebecca Dryer-Minnerly, et al.
Blood Advances|April 28, 2022
Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cellsAdam J Lamble, Regina M Myers, Agne Taraseviciute, et al.
Journal for Immunotherapy of Cancer|December 18, 2020
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse eventsMarcela V Maus, Sara Alexander, Michael R Bishop, et al.
Blood Advances|February 11, 2026
CCR4 expression defines a targetable subset of T-cell acute lymphoblastic leukemiaJason Xu, Michael McCoy, Zachary Martinez, et al.
Journal for Immunotherapy of Cancer|April 17, 2025
CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapyRegina M Myers, Amanda M DiNofia, Yimei Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2021
Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic LeukemiaRegina M Myers, Yimei Li, Allison Barz Leahy, et al.
Blood|January 31, 2016
Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failurePaul G Richardson, Marcie L Riches, Nancy A Kernan, et al.
Pageof 24